Month: September 2024

Aspocomp Group Plc, Stock Exchange Release, September 17, 2024, at 10:20 a.m. Finnish time The following members have been appointed to Aspocomp’s Shareholders’ Nomination Board: – Päivi Marttila, appointed by Etola Group and Erkki Etola – Kyösti Kakkonen, appointed by Joensuun Kauppa ja Kone Oy– Mikko Montonen, Aspocomp’s third largest shareholder Aspocomp’s Shareholders’ Nomination Board consists of three members who represent the company’s three largest shareholders. In addition, the Chairman of the company’s Board of Directors shall serve as an expert member of the Nomination Board unless he or she is appointed as an ordinary member of the Board. The three largest shareholders are determined annually based on the ownership information registered with the company’s shareholders’ register on the first business day...

Annual Report 2023/24 The Board of Directors of Rovsing A/S (Rovsing) has today approved the Annual Report for the financial year 2023/24. HIGHLIGHTS OF THE YEARDuring the financial year 2023/24, the revenue amounted to DKK 39,3 million (DKK 28,3 million in 2022/23), which is an increase of 39 % (DKK 10,9 million) and the highest revenue in recent history of Rovsing A/S.The EBITDA amounts to DKK 2,9 million (DKK 1,0 million in 2022/23) or an increase of DKK 1,9 million.The EBIT for the financial year 2023/24 amounts to DKK 1,0 million (DKK -1,0 million in 2022/23) and the net profit for the year amounts to DKK 0,2 million (DKK -1,7 million in 2022/23), a culmination of the turnaround process for Rovsing A/S, achieving a positive net result for first time in many years.The order backlog at 30 June 2024 stands at a solid DKK 38,8...

STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented positive top-line results from a clinical Phase 1/2 study with a potential first-in-class treatment of the rare bone disease osteogenesis imperfecta (OI). The results show that the treatment was safe and well tolerated and that fracture rates were reduced by over 75%. BOOST Pharma is developing a first-in-class and potentially groundbreaking cell-based treatment for the congenital disease osteogenesis imperfecta (OI), a condition characterized by fragile bones, constant fractures and deformities of bones. The treatment is based on a novel cell therapy, using human stem cells, with especially high bone-forming capabilities. The treatment is developed to be administered directly upon...

Company announcement 32/2024 Green Hydrogen Systems announces new CFO Kolding, Denmark, 17 September 2024 – Today, Green Hydrogen Systems has appointed Michael Kaalund as Chief Financial Officer (CFO) and member of the company’s Executive Management. Michael Kaalund will assume the position as of 1 November 2024. Michael brings over 20 years of international leadership experience, with a strong background in finance and general management across a wide range of industries.For the past 15 years, Michael has held CFO roles in both multinational corporations and local businesses, where he developed a comprehensive skill set in finance, IT, HR, and legal operations. His expertise in project-based industrial companies, coupled with his experience working with North European equity funds, will be instrumental as Green Hydrogen Systems...

       Investment of the Lac1 fund Paris, 17 September 2024 – The Board of Directors of Ipsos welcomes the decision of the Lac1 fund to become a major long-term shareholder in the company.  The Lac1 fund, managed by Bpifrance on behalf of French and international investors, is dedicated to the long-term support of large listed multinational companies. This is a positive testament to the importance of Ipsos’ business, which is to provide accurate and clear information and analysis on trends in society, markets and people. Ipsos has built a leading global position and intends to continue its development both in France and internationally. Through its investment, Lac1 is demonstrating its confidence in Ipsos’ long-term growth potential, given its geographic footprint, track record and innovative technology. Lac1’s investment...

Company Builds Global Intellectual Property Safeguards for Its Crop Protection Pipeline Ghent, Belgium, Sept. 17, 2024 (GLOBE NEWSWIRE) — Biotalys (Euronext BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced that it obtained patents for its first biofungicide, EVOCA™*, from both the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). Kevin Helash, Chief Executive Officer of Biotalys, said: “We are very pleased with the recent grants by the European and U.S. patent offices, which follow their thorough examination of our applications protecting the active ingredient of our protein-based biocontrol candidate, EVOCA. These decisions confirm the truly innovative nature of our solution and provide Biotalys...

Paris, 17 September 2024, 7.00 am (CET)    Rubis is organising today, 17 September 2024, in Paris (France), its “Photosol Day”. During this event dedicated to Photosol, Clarisse Gobin-Swiecznik (Managing Partner at Rubis), Robin Ucelli and David Guinard (co-founders and, respectively, Chairman and CEO of Photosol), along with other members of Rubis and Photosol management, will present a comprehensive analysis of the evolution of the photovoltaic markets, Photosol’s positioning, and the mid-term ambitions for the Company. On this occasion the Managing Partners stated: “At a time when the European market is being transformed to address energy security by decarbonising production, Rubis is powering ahead to lead the way as a global energy service provider. With a 30-year track record of value-creating growth and strategic acquisitions,...

Issuer name: IDEX Biometrics ASA Ex. date: 17 September 2024 Type of corporate action: Possible subsequent offering (repair issue) This information is published in accordance with the requirements of the Continuing Obligations.

In August, LHV’s lending continued at a faster than planned pace, which had a positive impact on the company’s profit number. The consolidated loan portfolio of AS LHV Group increased by EUR 87 million over the month. Deposits increased by EUR 254 million on a consolidated basis. The volume of the funds managed by LHV grew by EUR 4 million in August. Payments related to financial intermediaries amounted to 6.1 million per month. In August, the consolidated net profit of AS LHV Group was EUR 12.2 million. Among the subsidiaries, AS LHV Pank earned EUR 11.8 million, LHV Bank Ltd EUR 13 thousand, AS LHV Varahaldus EUR 240 thousand, and AS LHV Kindlustus EUR 129 thousand in net profit over the month. The number of the LHV Pank clients increased by 3,600. Strong results were driven by client activity and good home loan lending performance....